{
    "ticker": "ALVO",
    "name": "Alvotech",
    "description": "Alvotech is a biopharmaceutical company focused on the development and manufacturing of biosimilar medicines. Founded in 2013, Alvotech aims to improve patient access to high-quality biologic therapies through innovative products and robust development processes. The company specializes in monoclonal antibodies and has built a significant pipeline of biosimilar candidates that target various therapeutic areas, including oncology, immunology, and other chronic diseases. Based in Reykjavik, Iceland, Alvotech leverages advanced technology and a state-of-the-art manufacturing facility to ensure the production of safe and effective biosimilars. The company is dedicated to maintaining high standards of quality and compliance with regulatory requirements, with a mission to make biologics more accessible to patients worldwide. Alvotech collaborates with various partners to accelerate the development and commercialization of its products, striving to bring affordable alternatives to complex biologic therapies while addressing the growing demand for effective treatment options in the healthcare market.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Reykjavik, Iceland",
    "founded": "2013",
    "website": "https://www.alvotech.com",
    "ceo": "Robert Wessman",
    "social_media": {
        "twitter": "https://twitter.com/alvotech",
        "linkedin": "https://www.linkedin.com/company/alvotech/"
    },
    "investor_relations": "https://www.alvotech.com/investors",
    "key_executives": [
        {
            "name": "Robert Wessman",
            "position": "CEO"
        },
        {
            "name": "Hanna K. Arnlaugsson",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Biosimilars",
            "products": [
                "AVT02 (Biosimilar to Humira)",
                "AVT03 (Biosimilar to Avastin)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Alvotech | Leading Biopharmaceutical Company in Biosimilars",
        "meta_description": "Discover Alvotech, a leading biopharmaceutical company dedicated to developing high-quality biosimilars. Explore our innovative solutions and commitment to improving patient access.",
        "keywords": [
            "Alvotech",
            "Biosimilars",
            "Biopharmaceuticals",
            "Healthcare",
            "Biologic therapies",
            "Affordable medicines"
        ]
    },
    "faq": [
        {
            "question": "What is Alvotech known for?",
            "answer": "Alvotech is known for developing and manufacturing biosimilar medicines."
        },
        {
            "question": "Who is the CEO of Alvotech?",
            "answer": "Robert Wessman is the CEO of Alvotech."
        },
        {
            "question": "Where is Alvotech headquartered?",
            "answer": "Alvotech is headquartered in Reykjavik, Iceland."
        },
        {
            "question": "What are Alvotech's main products?",
            "answer": "Alvotech's main products include AVT02 (biosimilar to Humira) and AVT03 (biosimilar to Avastin)."
        },
        {
            "question": "When was Alvotech founded?",
            "answer": "Alvotech was founded in 2013."
        }
    ],
    "competitors": [
        "AMGN",
        "SNY",
        "HUM"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "GSK",
        "MRK"
    ]
}